Biotech Stock Collapses After Failed Drug Study

By Patrick Martin / March 08, 2018 / www.schaeffersresearch.com / Article Link

Vascular Biogenics Ltd (NASDAQ:VBLT) is the worst stock on the Nasdaq today, down 65% to trade at $2.38 -- and just off a new record low of $2.30 -- after the biotech's brain cancer drug failed to meet its late-stage study goals. However, the company said it believes VB-111 "may still hold promise for other indications we currently or may study in the future."

Prior to today's freefall, VBLT stock had tacked on 19% year-over-year, and had found support at its 200-day moving average, after pulling back from a two-year high of $9.05 on Nov. 16. Now, however, the security is on track for its worst single-day performance of all time.

Although the stock is currently short-sale restricted, plenty of short sellers are likely cheering today's collapse. Short interest increased by nearly 60% during the last two reporting periods, and now represents 6.7% of VBLT's total available float.

Analysts could re-think their bullish positions on the tanking drug name. The three brokerage firms tracking VBLT rate it a "strong buy," while the stock's average 12-month price-target of $14.75 represents a 520% premium to its current perch. Should VBLT continue to languish, it could promptdowngrades and/or price-target cuts.

Recent News

Gold stocks lead the large cap miners by far over H1/25

July 07, 2025 / www.canadianminingreport.com

Gold stocks up as the metal price and equities gain

July 07, 2025 / www.canadianminingreport.com

Mixed outlook for gold as it remains range bound for past three months

June 30, 2025 / www.canadianminingreport.com

Gold stocks down on flat metal price

June 30, 2025 / www.canadianminingreport.com

Gold stocks down on metal decline

June 23, 2025 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok